APA

Kullmann F., Hartmann A., Stöhr R., Messmann H., Dollinger M. M., Trojan J., Fuchs M., Hollerbach S., Harder J., Troppmann M., Kutscheidt A. & Endlicher E. (20111207). KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy. : Oncology.

Chicago

Kullmann F, Hartmann A, Stöhr R, Messmann H, Dollinger M M, Trojan J, Fuchs M, Hollerbach S, Harder J, Troppmann M, Kutscheidt A and Endlicher E. 20111207. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy. : Oncology.

Harvard

Kullmann F., Hartmann A., Stöhr R., Messmann H., Dollinger M. M., Trojan J., Fuchs M., Hollerbach S., Harder J., Troppmann M., Kutscheidt A. and Endlicher E. (20111207). KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy. : Oncology.

MLA

Kullmann F, Hartmann A, Stöhr R, Messmann H, Dollinger M M, Trojan J, Fuchs M, Hollerbach S, Harder J, Troppmann M, Kutscheidt A and Endlicher E. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy. : Oncology. 20111207.